Biopharmaceutical Industry Facing Hiring Difficulties and R&D Talent Gap, Finds PwC Health Research Institute ReportFebruary 4, 2013 8:00 am | News | Comments
A talent gap in the scientific workforce has biopharmaceutical companies searching outside for fresh skills and alternate approaches to R&D staffing, according to PwC's Health Research Institute (HRI) in a new report published today. New R&D organizational models based on partnerships, alliances and even crowd sourcing are changing talent needs.
OPKO Health, Inc. and PROLOR Biotech, Inc. announced that the companies have signed a definitive merger agreement under which OPKO will acquire PROLOR, a biopharmaceutical company focused on developing and commercializing longer-acting proprietary versions of already approved therapeutic proteins.
The global biotechnology industry continued on a path of recovery in 2012 as public companies in the sector achieved top- and bottom-line growth for the third straight year even while R&D spending remained under pressure at many companies.
ARCA biopharma, Inc. today announced that it has entered into an agreement with Medtronic, Inc. to collaborate on ARCA’s proposed clinical trial, known as GENETIC-AF. It is planned as a Phase 2b/3 clinical trial comparing Gencaro to metoprolol CR/XL for prevention of atrial fibrillation in patients with heart failure and reduced left ventricular ejection fraction.
PAREXEL International today released a new research report called Strategic Partnerships 2013. The report is the first to explore the current outsourcing landscape and the value Strategic Partnerships provide to biopharmaceutical companies of all sizes.
Top of the Pops: Single-use/disposable technologies gain in popularity and make their way up the chartsApril 18, 2013 11:40 am | by Mike Auerbach, Editor in Chief | Articles | Comments
If you were to liken the interest in single-use and disposable technologies in the pharmaceutical industry to terms we are familiar with when talking about hot web topics, you might say they have been “trending” for several years, or perhaps they have gone “viral” – but that might have some negative connotations in the industry, after all the industry is trying to eliminate viruses not promote them.
To aid their patient-focused efforts, many biopharmaceutical companies have turned to outside vendors. According to a study by Cutting Edge Information, drug companies without dedicated patient adherence teams allocate between 50% and 100% of their adherence budget to outsourced activities.
Olympus Biotech, a biopharmaceutical contract manufacturing organization (CMO) based in Lebanon, NH has seen plenty of change over its history and has emerged as a company with the expertise, experience, technologies and facilities to handle the inevitable changes the industry has in store.
By Scott Matusow, Contributor @scottmatusow ArQule (NASDAQ: ARQL) engages in the research and development of cancer therapeutics directed toward molecular targets and biological processes.The firm's lead product candidate Tivantinib (ARQ 197)...
Helix BioPharma Corp., a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today announced that it has entered into a definitive agreement for the sale of its Rivex Pharma division to Pharmascience Inc. for gross cash proceeds of up to $8.5 million.
Ipsen today announced that Inspiration Biopharmaceuticals Inc. (Inspiration) has commenced a voluntary reorganization case pursuant to Chapter 11’s provisions of the United States Bankruptcy Code. Inspiration's Chapter 11 case was filed on October 30, 2012 with the United States Bankruptcy Court in Boston, Massachusetts.
Developing a biopharmaceutical is just like developing a traditional small molecule therapeutic…except it is not. While the types of data needed for regulatory filings is the same, the significantly increased size and molecular complexity of biopharmaceuticals compared to small molecule therapeutics has a significant impact on the strategies and activities required for development.
Demand for biopharmaceuticals, especially monoclonal antibody-related products, continues to grow at a very healthy pace with total biopharmaceutical sales reaching $107 billion in 2010, or approximately 12% of the total pharmaceutical market.
Shares of Array BioPharma Inc. rose Tuesday, a day after the company reported it took a smaller loss in the fiscal fourth quarter as it continued development of some of its experimental drugs.Array is testing drugs for pain, cancer, blood and bone marrow disorders, and hepatitis C. The company...
Baxter's BioPharma Solutions Named "Best Contract Manufacturing Organization" for Third Consecutive Year at Vaccine Industry Excellence AwardsMay 9, 2012 6:21 am | by Baxter Healthcare | News | Comments
Baxter's BioPharma Solutions contract manufacturing business was named "Best Contract Manufacturing Organization" for the third consecutive year at the annual Vaccine Industry Excellence (VIE) Awards, announced on April 11, 2012, at the World Vaccine Congress in Washington, D.C.
The company has introduced a technologically advanced series of ports for the single-use bags used to transfer media and drug compounds in the biopharmaceutical industry.
The manufacturer of the HelixMark® line of fluid-handling products has announced that it will be supplying silicone tubing to the PharmBIO Products business unit of W. L. Gore & Associates, Inc.
MGB Biopharma and Almac's Sciences Business Unit have entered into a collaboration where Almac will manufacture the production of their lead gram positive antibacterial compound MGB-BP3. The compound is a DNA minor groove binder and is currently in pre-clinical development with IND filing targeted for Q3 2012.
Today there is a continued accelerating evolution in CMO and traditional biomanufacturing to Single-Use Systems (SUS) and disposable technologies. While this term, ‘disposable’ has been used since the inception of the technology in the 80’s, the polymeric device manufacturers found the ‘single-use’ moniker a more ‘green’ label for their products.
The InPro 6860i series features advanced optical technology and the proprietary Intelligent Sensor Management concept, which address the needs of a wide spectrum of applications in the production of biopharmaceuticals by combining easy handling with exceptional performance.
In this video interview, Endo Pharmaceuticals' Robert Cobuzzi speaks about the manufacturing and marketing challenges emerging biopharmaceutical companies will face in the near future and what the overall outlook is for this market segment.